SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech”, “AXIM” or “the Company”), an international healthcare solutions company targeting the diseases of ocular surface, today announced the launch of its new mobile optimized website designed to provide physicians, researchers and other healthcare professionals with personalized and timely information and resources that will enable them to make informed decisions when purchasing AXIM’s proprietary diagnostic tests.
This new AXIM Eye website features:
- Information on AXIM’s Point-of-Care FDA 501(k) optimized tests for lactoferrin and IgE designed to expedite the diagnosis of dry eye and ocular allergies.
- A research library where stakeholders can learn more about the biomarkers detected by AXIM’s assays.
- Guidelines for the CLIA Application Process, a requirement for optometrists and other physicians seeking to purchase, use and bill CMS for AXIM testing.
- An easy to use order form for those who have completed the CLIA application process.
“This comprehensive new website provides every visitor with the information they need to understand our products and place orders,” said John W. Huemoeller II, president and CEO of AXIM® Biotech. offers and help us streamline our sales process as we continue to grow. As part of our goal to help doctors save time and money by speeding up the diagnosis of a multitude of ophthalmic conditions, we hope this website makes it easier than ever for them to purchase the tools they need.
To learn more, please visit https://aximeye.com/.
About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as dry eye disease (DED) through testing for rapid diagnosis. The company has two of only five FDA-approved diagnostic tests for dye eye disease. For more information, please visit www.AXIMBiotech.com.
Statements made by Axim Biotechnologies Inc. in this press release may be “forward-looking” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform. Act of 1995. Forward-looking statements describe Axim’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to the lack of assurance that our diagnostic candidate will ever be approved for use by the US FDA or any equivalent foreign regulatory agency. In addition, Axim’s eye care diagnostic products that are FDA cleared may not be manufactured in sufficient quantities or that third parties with established ophthalmologists will enter into agreements or purchase from the Company, and even if The Company’s diagnostic candidates are successful, they may generate only limited revenue and profit for the Company. Various other factors are detailed from time to time in Axim’s reports and filings with the SEC, including our Annual Report on Form 10-K filed on April 15, 2022, and other reports we file with the SEC. , which are available at www.sec.gov . Axim Biotechnologies, Inc. undertakes no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unforeseen events, except as otherwise required by law. .
Kathryn Brown, Account Manager
6191 Cornerstone Ct., Ste. 114
San Diego, CA 92121, USA